Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 16/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.35 |
| ▸ | TSHR | P16473 | 8/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 10/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16180251 | 0.71 | CDC25B (0.39) | — | |
| SCHEMBL29965655 | 0.71 | CDC25B (0.39) | — | |
| SCHEMBL1180 | 0.71 | CDC25B (0.39) | — | |
| Methyl Alcohol SCHEMBL18284553 | 0.67 | CDC25B (0.36) | — | |
| SCHEMBL31337161 | 0.66 | EGFR (0.33) | EGFR | |
| SCHEMBL7737681 | 0.64 | CDC25B (0.41) | — | |
| SCHEMBL4574418 | 0.64 | CDC25B (0.38) | — | |
| SCHEMBL2975734 | 0.63 | CDC25B (0.48) | KMT2A | |
| SCHEMBL16681713 | 0.62 | EGFR (0.33) | EGFR | |
| SCHEMBL127479 | 0.62 | EGFR (0.50) | CYP1A2CYP3A4TSHRCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531696-B | Pyridopyrimidinones as NMDA receptor modulators and their use | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3283487-B1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | disclosed |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-3283487-A1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2018-02-21 | — | — | EP | disclosed |
| CN-107531696-A | Pyridopyrimidine ketone and their purposes as nmda receptor conditioning agent | 豪夫迈·罗氏有限公司 | 2018-01-02 | — | — | CN | disclosed |
| WO-2016166078-A1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | PDXK, XDH, PNPO | CYP1A2 58/4885CYP3A4 41/4885TSHR 1025/4885 |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | PDXK, XDH, PNPO | CYP1A2 58/4885CYP3A4 41/4885TSHR 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.